此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Evaluation of SCOUT DS Device in the Diagnosis of Diabetes

2012年7月3日 更新者:VeraLight, Inc.

An Evaluation of the SCOUT DS Device. Random Capillary Glucose and Leicester Diabetes Risk Score for Screening Subjects at Risk for Type 2 Diabetes

The primary objective is to identify compare SCOUT DS to random capillary glucose for identification of at-risk subjects with dysglycemia defined by hemoglobin A1c ≥ 6.0%.

研究概览

地位

未知

条件

详细说明

The study will complete up to 330 subjects at the clinical site to evaluate the accuracy of SCOUT DS, random capillary glucose (RCG) and the Leicester diabetes risk questionnaire for detecting prediabetes and undiagnosed type 2 diabetes in subjects at risk, but not having a pre-exiting diagnosis of type 2 diabetes. A point of care A1c measurement (Siemens DCA Vantage or Axis-Shield Afinion) will serve as the reference method for defining a positive screen (A1c ≥ 6.0%).

研究类型

观察性的

注册 (预期的)

330

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • West Yorkshire
      • Keighley、West Yorkshire、英国、BD20 6TD
        • 招聘中
        • Airedale General Hospital
        • 接触:
          • Richard Pope, MD
          • 电话号码:01535292760

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects must be 18 years of age or older

描述

Inclusion Criteria:

  • Age greater than or equal to 45 years

OR

Age 18 to 44 years and BMI > 25 kg/m² with one or more of the following risk factors:

  • Elevated waist circumference, > 35 inches for women and >40 inches for men
  • Habitually physically inactive (does not exercise regularly)
  • Has a first-degree relative with diabetes
  • Ethnicity with elevated risk for type 2 diabetes
  • Has delivered a baby weighing > 9 lb or diagnosed with gestational diabetes
  • Hypertension (≥130/≥ 85 mmHg) or being treated for hypertension
  • HDL cholesterol level < 35 mg/dL and/or a fasting triglyceride level ≥ 250 mg/dL or being treated for dyslipidemia with medication
  • Has been previously diagnosed with Polycystic Ovary Syndrome (PCOS)
  • Had impaired glucose tolerance or impaired fasting glucose on previous testing within the last 3 yrs
  • Conditions associated with insulin resistance such as acanthosis nigricans
  • History of vascular disease including heart attack, stroke, angina, coronary heart disease, atherosclerosis, congestive heart failure or peripheral arterial disease

Exclusion Criteria:

  • Under 18 years of age

    • Receiving investigational treatments in the past 14 days
    • Psychosocial issues that interfere with an ability to follow study procedures
    • Conditions that cause secondary diabetes including Cushing's syndrome, acromegaly, hemochromatosis, pancreatitis, or cystic fibrosis
    • Diagnosed with any type of diabetes, including type 1 or 2
    • Taking glucose lowering medications with the exception of metformin
    • Known to be pregnant
    • Receiving dialysis or having known renal compromise
    • Scars, tattoos, rashes or other disruption/discoloration on the left volar forearm.
    • Recent (within past month) or current oral steroid therapy or topical steroids applied to the left forearm; inhaled steroid therapy is not excluded
    • Current chemotherapy, or chemotherapy within the past 12 months
    • Known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Hemoglobin A1c
大体时间:Up to 6 months

A point of care A1c measurement will serve as the reference method for defining pre-diabetes (6.0% ≤ A1c ≤6.4%) and diabetes (A1c ≥ 6.5%)

The study will require one visit by each subject to the clinical site. The visit does not require fasting and can be done any time of day. The study (not including the IRB process and recruiting) is expected to last 6 months.

The target cohort comprises persons at risk for pre-diabetes and/or type 2 diabetes.

Up to 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Richard Pope, MD、Airedale General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2012年6月1日

研究注册日期

首次提交

2012年7月3日

首先提交符合 QC 标准的

2012年7月3日

首次发布 (估计)

2012年7月6日

研究记录更新

最后更新发布 (估计)

2012年7月6日

上次提交的符合 QC 标准的更新

2012年7月3日

最后验证

2012年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • VL2722

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅